Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Intellia Therapeutics ( (NTLA) ) has provided an update.
On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, showing significant reductions in plasma kallikrein and a favorable safety profile. The trial results, presented at a scientific meeting, suggest lonvo-z could become a one-time treatment option, with a Phase 3 trial ongoing. On November 10, 2025, Intellia also reported favorable Phase 1 data for nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with cardiomyopathy, demonstrating sustained serum TTR reduction and disease stabilization. However, the FDA placed a clinical hold on the Phase 3 trials for nex-z, impacting its development timeline.
The most recent analyst rating on (NTLA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
Intellia Therapeutics’ overall stock score is primarily influenced by its challenging financial performance and bearish technical indicators. The company’s high R&D expenses and negative cash flows are typical for a biotech firm in development, but they pose significant risks. The earnings call highlighted both progress and setbacks, with the clinical hold on nex-z trials being a major concern. Valuation metrics further reflect the company’s early-stage status and lack of profitability.
To see Spark’s full report on NTLA stock, click here.
More about Intellia Therapeutics
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing CRISPR-based therapies to address unmet medical needs and transform treatment paradigms. The company leverages its expertise in gene editing technology to create novel, first-in-class medicines.
Average Trading Volume: 7,573,281
Technical Sentiment Signal: Sell
Current Market Cap: $1.1B
Learn more about NTLA stock on TipRanks’ Stock Analysis page.